tiprankstipranks
Octave Specialty Group, Inc. (OSG)
NYSE:OSG
US Market
Want to see OSG full AI Analyst Report?

Octave Specialty Group (OSG) Earnings Dates, Call Summary & Reports

173 Followers

Earnings Data

Report Date
Aug 10, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
>-0.01
Last Year’s EPS
-0.22
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 06, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a strong operational and financial improvement story: very large revenue and adjusted-EBITDA gains in the Insurance Distribution segment, narrower GAAP losses, premium growth and loss-ratio improvement at Everspan on a pro forma basis, cost reductions, expanded capacity, and continued strategic progress on platform and AI initiatives. The quarter did include notable one-off headwinds — primarily a litigation settlement and related legal costs that materially inflated reported loss ratios, early-stage losses from newly launched MGAs, and ongoing non-recurring charges — but management quantified these items and highlighted pro forma metrics showing more normalized performance. On balance, the positive operational momentum and material improvements in non‑GAAP profitability and margins significantly outweigh the quarter’s lowlights.
Company Guidance
Management said 2026 guidance remains essentially unchanged from the February outlook, though Q1 came in ahead of plan and they will consider adjusting guidance in coming quarters; Q1 strength was led by Insurance Distribution where revenue rose 92% to $78.5M (42% organic growth) helped by the ArmadaCare acquisition (ArmadaCare organic +10%), driving Insurance Distribution adjusted EBITDA to $25.3M (≈32% margin) and pre-tax margin to 16.3%. Consolidated results improved materially — net loss narrowed to $6.9M (‑$0.13/sh) versus a $16.1M loss a year ago, consolidated EBITDA was $3.6M and consolidated adjusted EBITDA $20.1M, with adjusted net income $16.6M or $0.37/sh. For the year they expect organic growth to be the primary driver, A&H to represent ~30% of production, target 1–2 de novo MGA launches in 2026 (de novo costs reduced EBITDA by ~$1.1M in Q1), and no further NCI buy‑ins planned after the ~$44M spent this quarter; Insurance Distribution pro forma net debt/EBITDA was ~3.2x, bank spreads are ~275bps over SOFR, total available capacity has expanded from $1.5B to over $2B, and seasonality remains (Q1 strongest, Q4 second). Finally, Everspan’s Q1 metrics (GWP $104M, NPW $32M, NPE $20M) and a pro forma combined ratio ≈95% (accident year loss ratio ~54%, active programs ~57%) underpin the view that repositioning is on track.
Insurance Distribution Revenue Surge
Total revenues for the Insurance Distribution segment grew 92% year-over-year to $78.5 million in Q1 2026, driven by organic growth of 42% and the October 2025 acquisition of ArmadaCare.
Insurance Distribution Profitability Expansion
Adjusted EBITDA for the Insurance Distribution segment increased nearly fourfold to about $25 million, with adjusted EBITDA margins expanding to ~32% versus 17% a year ago.
Material Improvement in Consolidated Non-GAAP Earnings
Consolidated adjusted EBITDA to shareholders rose to $20.1 million from negative $1.3 million in Q1 2025 (improvement of ~$21.4 million). Consolidated adjusted net income to shareholders was $16.6 million, or $0.37 per share, versus a net loss of $6.0 million a year ago (improvement of $22.6 million).
Narrowing of GAAP Net Loss
Reported net loss to shareholders narrowed to $6.9 million, or $0.13 per share, in Q1 2026 from a net loss of $16.1 million, or $0.57 per share, in Q1 2025 — an improvement of 57%.
Everspan Premium Growth and Loss-Ratio Improvement
Everspan gross premiums written increased 19% to $104 million; net premiums written rose 80% to $32 million and earned premiums increased 28% to $20 million. Accident year loss ratio improved to 54% (active programs ~57%).
Corporate Expense Reduction Progress
Reported corporate expenses declined to just over $12 million from $15 million year-over-year; adjusted corporate expenses fell to $7.2 million from $10.6 million, reflecting cost reduction initiatives.
Balance Sheet / Capacity and Financing
Insurance distribution pro forma net debt-to-EBITDA on a TTM basis was ~3.2x at March 31, 2026. Bank facilities feature five-year tenors and an initial spread of 275 bps over SOFR (which steps down with leverage). Third‑party capacity increased from $1.5 billion entering 2026 to over $2 billion.
Strategic M&A and Capital Deployment
Completed buy-ins acquiring an additional 10% of Octave Ventures and stakes in four other MGAs for ~$44 million (funded with cash and expansion of the term loan). ArmadaCare itself grew revenue organically by ~10% versus its prior-year quarter.
Platform & AI Strategy
Company reiterated a clear strategy transitioning to a scalable MGA platform, with a two-track AI approach (proprietary systems and curated partners), selection of Anthropic as a core AI solution, and consolidation of MGAs on a homogeneous tech stack to accelerate data/AI benefits.
Strong Q1 Seasonality and Positive Outlook
Management characterized Q1 as a strong quarter, ahead of initial plan, and noted momentum with guidance unchanged for now and potential future adjustments; expects 1-2 new MGA startups in 2026 given deliberate selectivity.

Octave Specialty Group (OSG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

OSG Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 10, 2026
2026 (Q2)
>-0.01 / -
-0.22
May 06, 2026
2026 (Q1)
0.03 / 0.37
-0.13384.62% (+0.50)
Feb 23, 2026
2025 (Q4)
-0.15 / -0.02
-0.1283.33% (+0.10)
Nov 10, 2025
2025 (Q3)
-0.20 / -0.21
-0.4654.35% (+0.25)
Aug 07, 2025
2025 (Q2)
-0.19 / -0.22
0.18-222.22% (-0.40)
May 12, 2025
2025 (Q1)
-0.07 / -0.13
0.82-115.85% (-0.95)
Feb 26, 2025
2024 (Q4)
0.00 / -0.12
0.32-137.50% (-0.44)
Nov 12, 2024
2024 (Q3)
0.08 / -0.46
2-123.00% (-2.46)
Aug 05, 2024
2024 (Q2)
0.15 / 0.18
0.07157.14% (+0.11)
May 06, 2024
2024 (Q1)
0.09 / 0.82
-0.3373.33% (+1.12)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

OSG Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 06, 2026
$4.22$6.05+43.36%
Feb 23, 2026
$5.64$5.09-9.75%
Nov 10, 2025
$8.69$10.08+16.00%
Aug 07, 2025
$8.29$6.94-16.28%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Octave Specialty Group, Inc. (OSG) report earnings?
Octave Specialty Group, Inc. (OSG) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
    What is Octave Specialty Group, Inc. (OSG) earnings time?
    Octave Specialty Group, Inc. (OSG) earnings time is at Aug 10, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is OSG EPS forecast?
          OSG EPS forecast for the fiscal quarter 2026 (Q2) is >-0.01.